化合物及びその複合体

Title:

化合物及びその複合体

Document Type and Number:

Japanese Patent JP7210770

Kind Code:

B2

Abstract:

A conjugate comprising the following topoisomerase inhibitor derivative (A*):with a linker for connecting to a Ligand Unit, wherein the linker is attached in a cleavable manner to the amino residue. The Ligand Unit is preferably an antibody. Also provided is A* with the linking unit attached, and intermediates for their synthesis, as well as the released warhead.

More Like This:

JP5119153	New crystalline form of irinotecan hydrochloride
JP2023532153	Efficient method for extraction, separation and preparation of highly pure tetrodotoxin from puffer viscera
JP7290573	Fused Indazole Pyridone Compounds as Antiviral Agents

Inventors:

Howard, Philip Wilson
Dickinson, Nior
Kaiyo, Thais
Luke Masterson
Gownley, William

Application Number:

JP2021557758A

Publication Date:

January 23, 2023

Filing Date:

March 23, 2020

Export Citation:

Click for automatic bibliography generation Help

Assignee:

MedImmune Limited

International Classes:

C07D491/22; A61K31/4745; A61K47/60; A61K47/68; A61P35/00; A61P43/00; C07K5/06; C07K5/093; C07K5/103; C07K16/18

Domestic Patent References:

JP10095802A
JP2017501128A
JP2014520762A
JP2004529114A
JP6087746A
JP5059061A
JP5017479A
JP2138186A

Foreign References:

WO2012096832A1
WO2014121033A1

Other References:

J. Med. Chem. ,1998年,41(13) ,2308-2318,DOI: 10.1021/JM970765Q
Biomol Ther (Seoul).,2015年,23(6),493-509,DOI: 10.4062/biomolther.2015.116
ACS med. chem. lett.,2018年,9,56-60,DOI: 10.1021/acsmedchemlett.7b00436
Chem. Soc. Rev.,2015年,44,5495-5551,DOI: 10.1039/C5CS00048C

Attorney, Agent or Firm:

Michiko Matsutani
Yasushi Ochiai

Previous Patent: Separate authorization for content access and content delivery using multiple cryptographic digital ...

Next Patent: Glucoside derivatives as SGLT1 inhibitors and their use